Metri Bio

Executive Summary

Metri Bio is a private biotechnology company headquartered in San Francisco and Boston, founded in 2021 to develop first-in-class therapeutics for endometrial diseases, with an initial focus on endometriosis. The company leverages a proprietary 3D endometrial modeling platform to identify novel disease targets and advance targeted treatments, aiming to address the significant unmet need for over two billion women globally suffering from uterine diseases. Despite lacking disclosed funding or valuation, Metri Bio's platform-based approach positions it as an innovative player in the women's health space, particularly given the limited treatment options for endometriosis. The company's source listing on biopharmguy indicates it is actively building its pipeline and seeking visibility among investors and partners. Metri Bio’s conviction score reflects a balanced view of its potential and risks. The technology platform offers a differentiated approach to target discovery, which could lead to more effective therapies with fewer side effects. However, the company is at an early stage with no disclosed clinical or preclinical data, funding details, or partnership announcements. The lack of public information increases uncertainty, but the focus on a large underserved market and the proprietary platform provide a foundation for future growth. Key catalysts to watch include the release of preclinical proof-of-concept data, initiation of IND-enabling studies, and potential Series A financing.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data release60% success
• Q2 2026Series A financing announcement50% success
• Q4 2026Partnership or collaboration agreement40% success